BioInnovation Institute (BII) expands CardioMetabolic Bridge initiative to Munich and Berlin
The initiative offers funding, lab access and mentoring to help academic discoveries reach commercial development
Advertisement
BII, a leading international institute for life science and deep tech innovation, has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative. The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic diseases.
Supported by the Novo Nordisk Foundation, CardioMetabolic Bridge is a pan-European initiative designed to bridge the gap between academic research and commercial drug development. With Munich and Berlin joining London as key locations in the network, BII aims to strengthen access to outstanding scientific research, clinical expertise, entrepreneurial talent and industry networks across Europe.
Germany is home to a strong life science and medical research ecosystem, with world-class universities, hospitals, research institutions and biotech companies. The selection of Munich and Berlin reflects the strength and complementary capabilities of the two innovation environments and their potential to contribute to the next generation of cardiometabolic therapies.
“Germany has outstanding scientific capabilities and some of Europe's most dynamic life science ecosystems. We see significant opportunities in both Munich and Berlin to connect excellent research with the entrepreneurial expertise, infrastructure and industry networks needed to bring new therapies closer to patients. Establishing our presence in these two locations is an important step in expanding CardioMetabolic Bridge and strengthening Europe's ability to turn scientific discoveries into meaningful healthcare solutions,” says Jens Nielsen, CEO of BioInnovation Institute.
Connecting outstanding research with the resources to create impact
Despite Europe's strong position in cardiometabolic research, many promising scientific discoveries never make the transition from academic laboratories into drug development. Early-stage researchers and innovators often lack the funding, infrastructure, industry expertise and commercial support required to advance their discoveries.
CardioMetabolic Bridge seeks to address this challenge by providing selected research projects with early-stage funding, access to laboratory infrastructure, scientific and commercial mentoring, drug discovery and development expertise, and connections to investors and industry partners.
The initiative focuses on research addressing cardiometabolic diseases, including obesity, type 2 diabetes and cardiovascular disease, with the ambition of accelerating the development of next-generation therapeutics and supporting the creation of new biotech companies.
Through its interconnected European hubs, BII will work closely with universities, hospitals, research institutions and other ecosystem partners to identify promising discoveries and support their progression towards validated drug candidates and commercial opportunities.
Building a connected European innovation ecosystem
Munich and Berlin will become important parts of BII’s expanding European network, complementing the London hub at Victoria House in the Knowledge Quarter and BII’s headquarters in Copenhagen.
By establishing a presence in some of Europe's leading life science environments, BII aims to connect scientific excellence across national borders, facilitate collaboration and provide researchers with access to the expertise and resources needed to translate innovation into meaningful healthcare solutions.
“Our ambition with CardioMetabolic Bridge is to create a European platform where scientific excellence can be translated into real-world impact. By connecting leading research environments in different countries, we can help promising discoveries overcome the barriers that often prevent them from progressing beyond the academic laboratory. Ultimately, this is about accelerating the development of new treatments for people living with cardiometabolic diseases and strengthening Europe's life science innovation ecosystem,” says Jens Nielsen, CEO of BioInnovation Institute.
Other news from the department science
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.